LAG3 and hypophysitis: A recent study has shown that combination therapy with LAG-3 and PD-1 inhibitors resulted in a higher incidence of hypophysitis than PD-1 inhibitor monotherapy (2.5% vs. 0.8%, respectively) (2, 3).